ReCode Therapeutics has received clearance to initiate a Phase 1b multi-ascending dose study for RCT2100, an inhaled therapy for cystic fibrosis designed to deliver CFTR mRNA to target cells and promote the production of functional CFTR protein. The study will assess the safety and tolerability of RCT2100 in the 10% of CF patients who do not respond to, or experience side effects with, approved CFTR modulators. Patient enrollment will begin in September 2024 at sites in the Netherlands and France, with future expansion planned for the United Kingdom and the United States. RCT2100 is formulated using our proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) delivery platform. To find participating study sites, visit the page below: https://lnkd.in/gG6Y5JJu #CysticFibrosis #ClinicalTrials #TeamReCode #GeneticMedicine
Congrats to Recode on this achievement ... looking forward to positive results !
Well done
Helping you generate hands-off income through Real Estate without the hassle of Tenants, Termites and Toilets
2moCongratulations! Very exciting news. Signed, a 43 year old living with #cysticfibrosis